Thermo Fisher Scientific Inc.
Thermo Fisher Scientific is a global leader in scientific solutions, providing an unparalleled breadth of products and services for the continuous bioprocessing market. The company offers end-to-end bioprocess solutions, including the renowned HyPerforma™ single-use bioreactors, which are essential for intensified, continuous upstream processing. Their portfolio extends into continuous downstream components, such as chromatography systems and advanced filtration technologies, enabling manufacturers to transition seamlessly from batch to continuous workflows. Thermo Fisher’s commitment to process intensification is evident in its scalable platforms, which help biopharma companies achieve higher throughput, improved efficiency, and reduced facility footprint. A key focus is on integrating single-use technology with digital process analytics to allow for real-time monitoring and control, crucial elements for successful continuous operations. Their role is to supply the foundational infrastructure—from consumables and media to advanced instruments—that accelerates drug discovery and the commercial production of biologics, cementing their position as a central enabler of next-generation biomanufacturing.
Latest Market Research Report on Continuous Bioprocessing Download PDF Brochure Now
Sartorius AG
Sartorius AG is a prominent international partner in bioprocess technology, driving continuous bioprocessing primarily through its market-leading single-use and perfusion systems. The company is widely recognized for its BIOSTAT STR® single-use bioreactors, which are integral to intensified upstream processes, supporting high-cell-density cultures necessary for continuous production. Sartorius excels in providing modular platforms that enable seamless scale-up and digital integration. For example, their collaboration on the integration of their bioreactors with control systems simplifies equipment setup, reducing time-to-market for therapies. Furthermore, Sartorius provides continuous downstream solutions, including advanced filtration, purification, and membrane technologies that perfectly complement their upstream capabilities. By focusing on quality, reproducibility, and digitalization, Sartorius empowers pharmaceutical and biotechnology companies to adopt flexible, highly efficient, and resource-saving continuous manufacturing strategies for monoclonal antibodies, vaccines, and cell and gene therapies, thereby enhancing global biomanufacturing productivity.
Danaher Corporation
Danaher Corporation is a diversified global science and technology conglomerate whose significant presence in continuous bioprocessing is largely driven by its operating companies, notably Cytiva (formerly GE Healthcare Life Sciences) and Pall Corporation. Cytiva is a leader in single-use bioprocessing, known for its Xcellerex™ single-use bioreactors and its continuous chromatography systems, which are foundational for integrated continuous workflows. Pall Corporation contributes expertise in advanced separation, filtration, and continuous downstream processing, including technologies like alternating tangential flow (ATF) systems which are critical for high-cell-density perfusion. Danaher’s strategy focuses on delivering integrated, automated solutions that span the entire bioprocessing workflow. Their commitment includes expanding AI-driven bioreactor monitoring and providing precision consumables and equipment that ensure scalability and regulatory compliance. Through this comprehensive portfolio, Danaher is positioned as a critical technology provider, enabling the transition to next-generation precision medicine and flexible biomanufacturing across the globe.
Merck KGaA
Merck KGaA, known as MilliporeSigma in North America, is a global science and technology company that is a major force in the continuous bioprocessing market. The company offers an extensive and integrated suite of products and services, centered on its BioContinuum Platform, which is explicitly designed to streamline and enable continuous manufacturing. Merck’s expertise covers both upstream and downstream processes, providing innovative hardware, single-use assemblies, and process development services. They are particularly influential in separation technologies, including advanced microfiltration and ultrafiltration solutions critical for clarifying high-cell-density perfusions and continuous purification steps. The Mobius® single-use bioreactors and continuous chromatography systems are key elements of their offering, enabling biomanufacturers to enhance efficiency, reduce resource consumption, and achieve optimal production workflows. By providing comprehensive technical support and an integrated product platform, Merck KGaA actively drives the global shift toward continuous, intensified, and optimized biomanufacturing.
Repligen Corporation
Repligen Corporation is a bioprocessing-focused company that stands out for its pioneering and specialized technologies essential for intensified and continuous manufacturing. Repligen’s core expertise lies in continuous filtration and process analytics, making it an indispensable partner for upstream and downstream process intensification. The company is best known for its Alternating Tangential Flow (ATF) technology, which is the gold standard for high-cell-density perfusion culture, a critical enabler of continuous upstream bioprocessing. This technology significantly boosts productivity and ensures consistent manufacturing quality in both pilot and commercial settings. Additionally, Repligen provides single-use filtration and chromatography systems, such as their OPUS® pre-packed columns and the KrosFlo® TFF systems, which support continuous downstream purification. by focusing exclusively on highly specialized components that enhance bioprocess performance, Repligen has established itself as a key driver in making continuous bioprocessing reliable, scalable, and highly productive for the industry.
Lonza Group AG
Lonza Group AG is a leading global Contract Development and Manufacturing Organization (CDMO) that plays a crucial role in the adoption and implementation of continuous bioprocessing, particularly for complex and next-generation therapeutics. Unlike pure equipment manufacturers, Lonza’s contribution is focused on the practical application and integration of continuous processes for its biopharma clients. Lonza pioneers the integration of continuous processing for the manufacturing of biologics, as well as cell and gene therapies, offering a model for how these systems can be implemented successfully at a commercial scale. Their focus is on developing highly intensified and flexible manufacturing solutions that accelerate clinical development and commercialization. By building state-of-the-art facilities and developing robust, scalable continuous workflows, Lonza directly addresses the industry’s need for faster, more efficient, and cost-effective production of life-saving medicines, making them a service leader in the continuous bioprocessing ecosystem.
WuXi Biologics
WuXi Biologics is a global Contract Development and Manufacturing Organization (CDMO) that has firmly established itself as a leader in high-productivity biomanufacturing through its adoption of continuous processing. The company is highly recognized for its proprietary WuXiUP continuous bioprocessing platform, a fully integrated, end-to-end solution that spans from upstream production to downstream purification. This platform has demonstrated exceptional performance, achieving significantly higher productivity and product yields compared to traditional fed-batch processes. WuXi Biologics’ commitment to continuous technology allows for substantial increases in manufacturing efficiency and capacity while significantly reducing the facility footprint and overall production costs. Their large-scale manufacturing expansions, such as the construction of major biomanufacturing facilities utilizing single-use bioreactors and continuous technologies, exemplify their strategic focus. As a CDMO, WuXi Biologics’ successful deployment of its continuous platform provides an essential, high-volume manufacturing option for global biopharma companies.
FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies is a major Contract Development and Manufacturing Organization (CDMO) that specializes in the development and manufacturing of biologics, with a strong commitment to continuous bioprocessing as a core technology. The company leverages advanced platform technologies and custom process design to offer end-to-end continuous manufacturing solutions. Their expertise is particularly valuable in the production of complex molecules, including viral vectors for cell and gene therapy, and protein therapeutics. FUJIFILM Diosynth Biotechnologies focuses on innovative upstream and downstream integration, ensuring a seamless and intensified workflow. By adopting continuous processing, they enhance product quality consistency, improve manufacturing efficiency, and reduce the time-to-market for new therapies. This strategic investment in continuous technology positions them as a preferred partner for pharmaceutical companies seeking to innovate their manufacturing processes and accelerate the delivery of next-generation biopharmaceuticals.
Asahi Kasei Bioprocess America, Inc.
Asahi Kasei Bioprocess America, Inc., a subsidiary of the Japanese multinational Asahi Kasei, is a key player known for specialized equipment that enables continuous bioprocessing, particularly in the critical area of chromatography and filtration. The company’s technology is vital for the efficient and scalable purification of biopharmaceuticals, which forms the downstream segment of continuous bioprocessing. Asahi Kasei is renowned for its Planova™ filters, which are the industry standard for virus removal, and its line of high-performance continuous chromatography columns, which are essential for continuous downstream separation and purification. Their focus on highly efficient and reliable separation and filtration solutions directly supports the industry’s need for intensified and continuous workflows. By providing specialized, high-quality media and systems, Asahi Kasei enables biomanufacturers to achieve a consistent, high-purity product in a shorter amount of time, positioning the company as a strong, specialized enabler of continuous bioprocessing.
Eppendorf SE
Eppendorf SE is a globally recognized company known for its innovative laboratory equipment and solutions, and it plays a crucial role in the continuous bioprocessing market through its bioreactor systems. Eppendorf’s offerings include the BioFlo® and CelliGen® family of benchtop bioreactor systems, which are optimized for process development, scale-up, and small-scale manufacturing of continuous cultures. These systems are essential for early-stage process intensification, allowing researchers to develop and optimize the high-cell-density perfusion cultures that are the foundation of continuous upstream bioprocessing. The company’s bioreactors are designed for maximum flexibility, supporting both single-use and autoclavable vessels with advanced digital process control and monitoring. By providing reliable, high-quality, and digitally integrated benchtop solutions, Eppendorf supports academic and R&D institutes, as well as biopharma companies, in their initial steps toward developing and validating robust, scalable continuous bioprocessing workflows.
Latest Market Research Report on Continuous Bioprocessing Download PDF Brochure Now